August 5, 2022
Treatment Approaches for Advanced Hepatocellular Carcinoma: Insight From the 2022 Gastrointestinal Cancers Symposium BookmarkGeorge Lundberg, MD
In this article for Cancer Therapy Advisor, Dr. Shaalan Beg shares updates from the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium on treatments for advanced hepatocellular carcinoma.
July 28, 2021
New Approvals for Liver Cancer Mark ‘Golden Age’ of Treatment BookmarkGeorge Lundberg, MD
Reported in Healio: After decades of little or no progress, many new clinical trials testing targeted and immunotherapy drugs—especially in combinations—are showing that they have real value in treating primary liver cancer (hepatocellular carcinoma).
July 14, 2021
Emma Shtivelman, PhD
I last wrote about melanoma treatment more than 2 years ago, a fairly long time in the evolution of treatments for this type of cancer. Just as a refresher, the current mainstays of drugs to treat melanoma fall into two categories: Immune checkpoint inhibitors (ICI), antibody drugs that bind to proteins found on the immune system’s T cells—namely, PD-1 (which is targeted by the… Read more »
April 12, 2021
Lenvatinib/Pembrolizumab Improves Survival in Advanced Endometrial Cancer BookmarkGeorge Lundberg, MD
The ASCO Post reports on new results from a clinical trial testing a combination of the drugs lenvatinib and pembrolizumab in people with advanced or recurrent endometrial cancer. The results show that, compared to standard chemotherapy, this drug combo improves both overall and progression-free survival—according to both statistical and clinical analysis.
December 2, 2019
Pembrolizumab Plus Lenvatinib Approved for Endometrial Cancer BookmarkGeorge Lundberg, MD
Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved a new combination therapy for certain advanced endometrial cancers.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.